Background: ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC.
They have achieved better results in prolonging the progression free survival and improving …

Purpose The current study was carried out to compare the effectiveness and safety of
different ALK inhibitors in treating ALK+ NSCLC. Methods Progression‐free survival (PFS) …

8008 Background: The ALK inhibitor crizotinib is approved for patients (pts) with ALK-
rearranged (ALK+) NSCLC, but most pts progress within a year and CNS progression is …

Background Mature progression-free survival (PFS) data from the phase III J-ALEX study
showed superiority for alectinib versus crizotinib [hazard ratio (HR) 0.37, 95% confidence …

LBA9008 Background: Alectinib, a TKI targeting ALK, has shown robust efficacy in crizotinib-
naïve/resistant ALK+ NSCLC. J-ALEX showed superiority of alectinib 300mg BID vs …

Abstract Objectives The J-ALEX study compared the efficacy and safety of alectinib with
crizotinib in Japanese patients with advanced ALK-positive non-small-cell lung cancer …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …

Our review will discuss the recent phase III data with ceritinib and alectinib as well as clinical
trials with other ALK inhibitors. We will also address two important issues in the …

PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
demonstrated superior progression-free survival (PFS) and improved health-related quality …

9008 Background: ALC showed promising efficacy and tolerability in the phase I/II study (AF-
001JP). Here, we conducted the randomized open-label phase III trial (J-ALEX study …